Dimethylformamide → (R)-2-(1-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)-1H-imidazol-4-yl)acetonitrile

HRID 2093685

反応式

HRID 2093685 の反応式
[NH:1]1[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]1.CN[C@@H]1[CH2:16][CH2:15][CH2:14][CH2:13][C@H:12]1[NH:17][CH3:18].C([O-])([O-])=O.[Cs+].[Cs+].[CH3:25][N:26]([CH:28]=[O:29])[CH3:27]>>[CH:12]1([N:17]2[C:18]3[N:3]=[C:2]([N:1]4[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]4)[N:1]=[CH:5][C:25]=3[N:26]([CH3:27])[C:28](=[O:29])[C@H:4]2[CH2:6][CH3:7])[CH2:13][CH2:14][CH2:15][CH2:16]1

参加物

5

反応条件

温度
110 °C

実験手順

A mixture of intermediate B (150 mg, 0.509 mmol), 2-(1H-imidazol-4-yl)acetonitrile (1.01 mmol, 2 equivalents, 108 mg), Cut (0.1 equivalents, 0.0509 mmol, 10 mg), trans-1,2 bis(methylamino)cyclohexane (14 mg, 0.102 mmol) and Cs2CO3 (1.01 mmol, 331 mg) in DMF (1 mL) was purged with nitrogen and was subsequently heated in a sealed vial at 110° C. for 18 h. The reaction was diluted with ethyl acetate, filtered through Celite and evaporated. The residue was purified by reverse phase preparative HPLC and lyophilized to give the title compound (185 mg). 1H NMR (CDCl3) δ: 8.66 (s, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 4.31-4.37 (m, 2H), 3.91 (s, 2H), 3.38 (s, 3H), 1.70-2.13 (m, 10H), and 0.93 ppm (t, J=7.4 Hz, 3H); LCMS: 366.1 m/z (M+H)+; ret. Time: 3.444 min (Analytical Method A).

後処理

  1. customwas purged with nitrogen
  2. additionThe reaction was diluted with ethyl acetate
  3. filtrationfiltered through Celite
  4. customevaporated
  5. customThe residue was purified by reverse phase preparative HPLC

出典と根拠

ORDレコード
ord-5e15af548d8e4daab36392fa9991aa61
出典データセット
uspto-grants-2013_05
特許番号
US08445503B2

関連ノート

読み込み中…